Young David 4

What Happened
David Young, President of Research & Development and a director at Processa Pharmaceuticals (PCSA), reported a purchase of 2,067 shares on 2026-06-15. The Form 4 lists the transaction as a purchase (code P) at $2.22 per share for a total of $4,589. This was an acquisition (insider buying), which investors often view as a more informative action than routine sales.

Key Details

• Transaction date: 2026-06-15
• Filing date: 2026-06-16 (filed within the standard Form 4 reporting window)
• Shares purchased: 2,067 at $2.22 per share
• Total value: $4,589
• Transaction type/code: P — reported as an open-market or private purchase (Form 4 does not specify which)
• Shares owned after transaction: Not disclosed on the Form 4 provided
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other special footnotes were indicated in the filing

Context
Insider purchases can be interpreted as a positive signal because executives are buying company stock, but they do not guarantee future performance and motives are not disclosed. The dollar amount here is modest; retail investors should consider this alongside other filings, company news, and financials before drawing conclusions.